RE:Word of adviceThose are some decent points, some of which I've made before, but I don't completely agree.
Yes, Canada's debt problem is pretty significant and inflation picking up along with interest rates are a potential headwind and expensive specialty products may suffer.
However, Ceapro's sales are very much existant and growing. In 2017, if you smooth out the quarters when the new plant came on the sales are roughly $3.4M, which we've exceeded last quarter at $3.6M. The stock plummeted from a relative standpoint from sky high valuation at $2/share. However, if you smooth that out as well, the share price has been gaining lots of traction since management took over in 2012. The growth has been about 5X at today's price. Also, now that the transitional year is behind us, the new products can begin to show some traction on the bottom line.
Ultimately, the company is in solid position with potential headwinds but also significant tailwinds and at the current valuation it makes sense to bet on those tailwinds with a 2-3 year time horizon.